Stockreport

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

Exscientia Plc - American Depositary Shares  (EXAI) 
PDF Demonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignanciesData highlights efficacy of ‘539 in a preclinical AML model, with limited [Read more]